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saline ischemic group as compared with all other groups. Kid-Simultaneous blockade of endothelin A and B receptors in
ney weights were increased in all ischemic groups, but no differ-ischemic acute renal failure is detrimental to long-term kidney
ences were observed between the saline ischemic group andfunction.
ETR antagonist-treated groups. Immunohistochemistry re-Background. There is growing evidence of long-term patho-
vealed relationships between Mo and M f , MF, and tubulointer-logical consequences following renal ischemia. Endothelin
stitial collagen III, where the saline ischemic and ETA/ETB(ET) receptor antagonists have proved beneficial in the treat-
groups were increased as compared with the sham ischemic andment of ischemic acute renal failure (IARF); however, the
ETA groups. There was no change observed in tubulointerstitiallong-term outcomes have not been assessed in this disease.
collagen IV accumulation. The largest number of proliferatingMethods. Experimental IARF was induced in uninephrec-
cells was demonstrated in the ETA/ETB group, whereas apo-tomized female Sprague-Dawley rats (N 5 8) by clamping
ptotic cells were identified in small amounts in all groups, withof the renal pedicle. At 24-hours postischemia, a once-only
the largest number being found in the saline ischemic group.administration of drug or vehicle was given. One ischemic
Conclusions. Renal ischemia appears to have long-termgroup received saline only (saline ischemic), and two other
functional and pathological consequences that can be pre-ischemic groups received either SB 234551 (ETA receptor an-
vented by treatment with ETA receptor antagonists. Blockadetagonist, ETA group) or SB 209670 (ETA and ETB receptor
of both ETA and ETB receptors, however, appears to be detri-antagonist, ETA/ETB group). A uninephrectomized control
mental to long-term kidney function.group was sham operated to simulate operative conditions
without ischemia and was given a once-only saline infusion
(sham ischemic). All groups were sacrificed at six-months post-
ischemia. Serum creatinine was assessed daily for one week
The long-term consequences of acute renal ischemiaand then every four weeks. Glomerular filtration rates (GFRs),
have not been extensively investigated. Although it issystolic blood pressure, 24-hour urine collection, and creatinine
clearance were performed just prior to sacrifice. Immunohisto- generally assumed that recovery from acute ischemia is
chemistry for monocytes and macrophages (Mo and M f ), myo- complete, there is mounting experimental evidence to
fibroblasts (MF, a-SMA), collagen IV, and collagen III was suggest that this may not be so. Increases in cellular
also evaluated. Cell kinetics were studied by immunostaining
infiltrates and mRNA for extracellular matrix compo-for proliferating cell nuclear antigen (PCNA) and by TUNEL.
nents have been identified at 24-weeks postischemic in-Results. Urinalysis revealed significant increases in urinary
protein and albumin in the ETA/ETB group when compared jury [1]. Pagtalunan et al demonstrated tubulointerstitial
with all other groups. GFRs and creatinine clearance were also disease accompanied by proteinuria and widespread seg-
decreased significantly in the ETA/ETB group. Urine albumin, mental glomerular tuft injury at 20-weeks postischemiaprotein, GFR, and creatinine clearance in the ETA group, how- [2]. Likewise, in a rat model of ischemic acute renalever, were not different from the sham ischemic and saline
failure (IARF), our group has also reported increases inischemic groups. Systolic blood pressure was increased in the
interstitial area and tubulointerstitial collagen III accu-
mulation at 180 days following renal ischemia [3].
1 See Editorial by Safirstein, p. 1590 Endothelin (ET) is increasingly recognized as a major
regulator of cell function in both renal and nonrenalKey words: endothelin receptor antagonists, end-stage renal disease,
injury, tubulointerstitial disease, proteinuria, SB 243551. diseases. Most patients with a variety of renal diseases
have increased plasma ET [4–6], as do patients withReceived for publication June 26, 2000
chronic renal failure [7, 8]. Animal studies have alsoand in revised form September 27, 2000
Accepted for publication October 11, 2000 shown chronic changes in mRNA for ET, which peaked
20 months after ischemia/reperfusion injury in the rat [6].Ó 2001 by the International Society of Nephrology
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Several studies have shown short-term beneficial ef- ficed at six-months postischemia or sham operation. Sys-
tolic blood pressure, 24-hour urine collection, and glo-fects of ET blockade in various acute experimental mod-
els, including recovery from IARF [9–11]. Most of these merular filtration rate (GFR) were performed just prior
to sacrifice at six months.studies have concentrated, however, on blockade of the
ETA receptor with beneficial effects being observed up All procedures were performed in accordance with
the Animal Ethics Committee of the Royal Children’sto seven-days postischemia. Blockade of both ETA and
ETB receptors with SB 209670 has also shown short-term Hospital Research Institute.
beneficial effects in ischemic ARF [9, 12]. Likewise in a
Serum creatininemodel of renal transplantation, bosentan, a nonselective
ETA/ETB receptor antagonist, protected kidneys from Daily blood samples were collected for one-week post-
ischemia followed by one sample each four weeks untilcold ischemia-reperfusion injury [13]. These authors es-
tablished a link between ET and function by demonstra- sacrifice. Serum was prepared from clotted blood and
analyzed for creatinine by standard routine spectropho-ting increases in renal ET mRNA and immunoreactive
tissue ET in the reperfusion phase, which contributed to tometry.
the deterioration of renal function. However, as with any
Urinary albumin, protein and creatininenew prospective drug, the long-term outcome of treatment
with ET receptor antagonists (ETR) remains uncertain. Animals were placed in metabolic cages for 24 hours
to collect urine. Urinary volume was measured, and sam-Therefore, this study addressed the long-term renal
benefits and risks associated with the blockade of ET ples were stored at 2208C until use. Urinary protein and
creatinine were assayed by routine biochemical methodsreceptors. Markers of renal function and renal pathology
were studied in a model of IARF at six months postische- at the Royal Children’s Hospital biochemistry depart-
ment. Urinary albumin concentration was determinedmia following a once-only treatment with one of SB
243551 (ETA) or SB 209670 (ETA/ETB) receptor antago- by radioimmunoassay (RIA). Briefly, duplicate 100 mL
aliquots of urine were taken and 100 mL of 125I albuminnists. The results indicated that the short-term beneficial
effects of blockade of both ETA and ETB receptors with (20000 cpm), 100 mL of rabbit anti-rat albumin antibody
(1:4000), and 300 mL of incubation buffer were added.SB 209670 were in direct contrast to the detrimental
renal effects of this drug observed at 180-days postis- A standard curve for albumin was prepared (62.5 to 4000
ng/mL). The tubes were vortexed and incubated at roomchemia.
temperature (RT) for five hours. A secondary antialbu-
min antibody (1:40) was added followed by 750 mL of
METHODS
polyethylene glycol (PEG). Total counts were then as-
Experimental model sessed after centrifugation. Albumin excretion was then
subsequently calculated (mg/24 h).The animal model used was based on previous studies
[3, 9]. A right unilateral nephrectomy was performed
Systolic blood pressurethrough a flank incision in 32 female Sprague-Dawley
rats of approximately 200 g body wt, under 4% fluothane Systolic blood pressure was measured by indirect tail-
cuff plethysmography in prewarmed, unanesthetized ani-in oxygen. Five days later, an ischemic injury was induced
in 24 rats by occlusion of the left renal pedicle with mals as previously described [14]. Animals were warmed
with a heat lamp for 10 minutes before measurementarterial clamps for 45 minutes. The remaining eight ani-
mals had a sham operation, consisting of a flank incision and then immobilized in a chamber, which allowed for
adequate access for the tail cuff (Harvard Instruments,and dissection of the renal pedicle without occlusion
(sham ischemic group). Kent, UK). An occlusive tail cuff plethysmograph was
attached to a pneumatic pulse transducer and oscillo-Twenty-four hours later, the four groups (N 5 8 per
group) had a once-only administration of drug or vehicle. scope (Harvard Instruments). Systolic blood pressure
was calculated from the mean value of three measure-Two groups of ischemic animals were treated intrave-
nously with ET receptor antagonists: the ETA receptor ments estimated from the oscillographs produced.
antagonist (SB 234551) or ETA and ETB receptor antago-
Glomerular filtration ratenist (SB 209670). The animals were given an initial 5
mg/kg bolus, followed by 15 mg/kg/h (SB 234551, ETA) Glomerular filtration rate was estimated in unanesthe-
tized animals as previously described [15]. A dosage ofor 1 mg/kg/min (SB 209670, ETA and ETB) in a final
volume of 6 mL over three hours as a once-only treat- 99Technicium-bound DTPA (0.26 mCi) was injected into
each rat via the tail vein using an insulin syringe. A timement. Two control groups were used, saline ischemic and
sham ischemic groups, where saline was administered at lapse of exactly 43 minutes was observed, after which a
1 mL blood sample was taken from the tail vein with a24-hour postischemia/sham operation at 2 mL/h for three
hours, to mimic treatment infusions. Animals were sacri- small-gauge needle. Plasma was then counted in a
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gamma counter (Packard Instrument Company, Meri- toxylin and mounted in dePex (BDH). Negative control
den, CT, USA), and the GFR was estimated by manipu- sections with the omission of the primary antibody were
lation of a set formula. stained as per the protocol described previously in this
article. Positive control tissues with previously ascer-
Histology tained staining for the antibodies mentioned previously
Hematoxylin and eosin. Formalin-fixed paraffin sec- were also included. Activity of the ABC Elite was tested
tions 2 mm thick were dewaxed and hydrated. Sections by incubation of a small volume with freshly prepared
were stained for five minutes in Harris hematoxylin, DAB.
washed in Scott’s tap water for 10 seconds, and then
TUNELimmersed in eosin Y for five minutes. Sections were then
dehydrated through graded ethanols, cleared in xylene, DNA fragmentation is a hallmark of cells in which
and mounted in dePex (BDH Chemicals, Poole, UK). endonucleases have been activated during the process
Combined silver methenamine/masson trichrome. of cell death [17]. Cell death was identified by 39 in
Formalin-fixed paraffin sections 2 mm thick were de- situ end labeling of fragmented DNA with biotinylated
waxed and brought to water through graded alcohols. deoxyuridine-triphosphate (dUTP) [18]. Terminal trans-
Sections were treated with 0.5% periodic acid for 30 ferase labeled the nicked DNA with labeled dUTP,
minutes, washed, and then stained in silver methenamine which was subsequently detected by immunohistochemi-
solution at 50 to 608C until sections turned brown (,60 cal techniques [19].
min). Staining was then checked microscopically until Sections of formalin-fixed tissue were dewaxed and
sufficient impregnation was achieved. Fixation was per- hydrated. Following digestion with proteinase K (2
formed in 5% sodium thiosulfate for 20 seconds, and mg/mL; Sigma, St. Louis, MO, USA), sections were con-
then sections were placed into Harris hematoxylin for secutively washed in TdT buffer (0.5 mol/L cacodylate,
five minutes. Sections were dipped into Scott’s tap water pH 6.8, 1 mmol/L cobalt chloride, 0.15 mol/L NaCl) and
and then stained in Masson red for five minutes. Without then incubated at 378C with TdT (25 U; Boehringer-
rinsing, the sections were then placed into 1% aqueous Mannheim, Mannheim, Germany) and biotinylated dUTP
phosphotungstic acid for five minutes. Counterstaining (1 nmol/mL). After washing in TB buffer (300 mmol/L
was performed in 1% aqueous light green for five min- NaCl, 30 mmol/L sodium citrate) to terminate the reac-
utes, and then sections were quickly dehydrated through tion, incorporation of biotinylated dUTP was detected
graded alcohols, cleared in xylene, and mounted in dePex by a modification of the ABC method [16]. Horseradish
(BDH). Quantitation of interstitial area was performed peroxidase-conjugated strepavidin-biotin complex was
on these sections. applied (Vector), the sections were developed with DAB
and counterstained in Harris hematoxylin. A mouseImmunohistochemistry
spleen with increased apoptosis was used as a positive
A modification of the ABC immunoglobulin enzyme
control for TUNEL. The omission of TdT during dUTP
bridge technique [16] was used for immunohistochemis-
nick end labeling provided a negative control [19].
try. Formalin-fixed paraffin sections were dewaxed and
hydrated. Following digestion of tissue, endogenous per- Point counting
oxidase activity was eliminated by treatment with metha-
Point counting was performed in the renal cortex andnol containing 0.03% hydrogen peroxide for 20 minutes.
corticomedullary junction for each animal following rou-Sections were then incubated with normal serum for
tine established methods [20, 21]. In each field, 100 points20 minutes before incubation with primary antibody for
were counted on a 1 cm2 eyepiece graticule with 10 equi-one hour. Primary antibodies used were collagens IV
distant grid lines. A total of 12 high-power fields (3400)and III (Southern Biotechnology Associates Inc., Bir-
per section was counted for each animal in all groups (8mingham, AL, USA), a-SMA (Dako Corporation, Car-
cortical and 4 corticomedullary fields). Each high-powerpinteria, CA, USA), ED-1 for Mo and M f (Serotec Ltd.,
field was 0.076 mm2, with 0.91 mm2 being the total areaOxford, UK), and proliferating cell nuclear antigen
counted per slide. % Fractional area (FA) was calculated(PCNA; Dako). Tissue sections were consecutively
as follows [21]:stained with biotinylated IgG for 10 minutes and avidin-
biotin horseradish peroxidase complex for 15 minutes %FA
(Vectastain ABC ELITE kit; Vector Laboratories Inc.
Burlingame, CA, USA). Peroxidase activity was demon- 5
number of grid intersections with positive staining
total number of grid intersectionsstrated by a substrate solution of 3,39-diaminobenzidine
tetrahydrochloride (DAB; Dako) in 0.1 mol/L phos-
3 100
phate-buffered saline (PBS) containing 0.03% hydrogen
peroxide. Sections were counterstained in Harris’ hema- This corresponds to the percentage of positive area in
Forbes et al: Long-term blockade of ET in IARF1336
the total area counted of the section. Positive staining
refers to the brown colorimetric peroxidase product
(DAB) for immunohistochemistry and interstitial area
on silver methenamine/masson trichrome.
TUNEL and PCNA quantitation were undertaken at
31000 on tubular, interstitial, and other (vascular and
glomerular) cells under oil immersion, where a total of
20 graticule fields were counted (,1000 nuclei per slide
20.61 mm2 total area/slide), and the results are expressed
as number of positive cells/total number of cells counted.
Statistical analysis
Statistical analysis was performed between experimen-
tal groups by applying Kruskal–Wallis nonparametric
testing with correction for multiple comparisons. Sig-
nificance was stated at P , 0.05. Data are expressed as
mean 6 SEM unless otherwise stated.
RESULTS
Functional parameters
Serum creatinine concentrations. Serum creatinine con-
centrations were consistent among groups with renal is-
chemia. There was a peak observed at two-days postis-
chemia (0.42 6 0.10) before serum creatinines returned
to approximately 0.05 mmol/L at eight days. This re-
mained stable for the six-month study period in all ische-
mic groups. There was, however, a significant difference
Fig. 1. Functional parameters studied at six-months postischemia. (A)
observed between ischemic groups and the sham ische- Glomerular filtration rates (GFRs). (B) Urinary protein concentrations.
#P , 0.05 as compared with saline ischemic group; *P , 0.05 as com-mic group (P , 0.05 vs. saline ischemic group). The sham
pared with sham ischemic group. Standard errors of the mean are shownischemic group showed no increase in serum creatinine
by the error bars on all graphs (N 5 8 for all groups).
for the duration of the study. This was consistent with
previous studies [1, 8], and therefore, the data are not
shown.
Glomerular filtration rate and creatinine clearance. sacrifice was significantly increased in all ischemic groups
when compared with the sham ischemic group (P ,GFR measured radioactively was significantly decreased
in the ETA/ETB group, when compared with both the 0.05; Fig. 1B). The ETA/ETB group also had increased
proteinuria when compared with the saline ischemicsham ischemic and the saline ischemic group at six
months (P , 0.05; Fig. 1A). There was also a significant group (P , 0.05). Urinary albumin excretion demon-
strated a similar trend to that of urinary protein, althoughdifference observed between ETA group and the ETA/
ETB group (P , 0.05; Fig. 1A). There was no difference no significant difference was observed among groups
(Table 1).observed among other groups. Although the results ob-
tained for creatinine clearance were lower than GFR
Weight measuresvalues obtained radioactively, the data followed the same
pattern. The ETA/ETB group had significantly lower cre- During the first month postischemia or sham, no differ-
ence was observed in body weight among the groups.atinine clearances and urine volumes than all other
groups (P , 0.05; Table 1). At one and two months postischemia, the saline ischemic
group had significantly lower body weights than the ETRSystolic blood pressure. Mean systolic blood pressure
was significantly decreased in both the ETR antagonist antagonist-treated groups (data not shown). At six
months postischemia, there was no difference observedtreated groups when compared with saline ischemic ani-
mals at six months (Table 1). Blood pressures were also among groups (Table 1).
Kidneys from animals in the ischemic groups weresignificantly lower in sham ischemic versus saline ische-
mic animals (P , 0.05). significantly increased in size as compared with kidneys
from sham ischemic animals (P , 0.05; Table 1). ThereUrinary protein and albumin excretion. Proteinuria
calculated from 24-hour urine collection just prior to was no difference observed between ETR antagonist-
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Table 1. Functional data for all groups at six months
Saline SB 234551 SB 209670 Sham
ischemic ETA ETA/ETB ischemic
Parameter N 5 8 N 5 8 N 5 7 N 5 8
Systolic blood pressure mm Hg 190615 147624a 153622a 154618a
Urine albumin mg/24 h 70.9695.4 33.1623.1 70.4654.6 14.564.08
Creatinine clearance mL/min/kg 4.2060.50 4.1160.91 2.8760.45a,b 4.2260.62
24-hour urine volume mL 13.265.9 14.165.0 6.361.9a,b 12.465.7
Body weight g 292614.9 324629.6 312627 301636
Kidney weight g 1.8060.16 1.8960.19 1.9960.23 1.2160.12a
Heart weight g 1.1660.09 1.1660.14 1.1660.09 1.0560.08a
Systolic blood pressure is expressed as mean 6 SEM; all other data are expressed as mean 6 SD.
a P , 0.05 vs. saline ischaemic group
b P , 0.05 vs. ETA group
treated and the saline ischemic group at any time. Ani- and the ETA/ETB group when compared with the sham
ischemic group (P , 0.05; Fig. 3B). The ETA groupmals that had renal ischemia had larger hearts as com-
pared with the sham ischemic group (P , 0.05), although showed a decrease in collagen III accumulation when
compared to the saline ischemic group (P , 0.05).there was no significant difference in heart weight be-
tween treated and untreated ischemic groups (Table 1). Tubulointerstitial collagen IV. There were no signifi-
cant differences observed among groups for tubulointer-
Pathological parameters stitial collagen IV accumulation (Table 2).
Histologic changes. Numerous tubular casts were evi-
Cellular kineticsdent throughout the cortex and medulla of the ETA/ETB
group (Fig. 2). These casts were not evident in other Proliferating cells. Cells demonstrating staining for
PCNA were found in both the tubules and interstitiumgroups. This group also had vacuolization and disrupted
brush border in proximal tubules. There were also focal in all groups. A small number of proliferating glomerular
and vascular cells were observed in the ETA/ETB group.areas of interstitial accumulation and thickened tubular
basement membranes evident in the saline ischemic ani- While tubule and interstitial cell proliferation was in-
mals and those treated with SB 209670 ETA/ETB (Fig. creased in the saline ischemic group (P , 0.05 vs. sham;
2). These were not evident in the sham ischemic group Fig. 4), proliferation in the ETA antagonist group did not
or the ETA group. There were no differences observed differ from that observed in the sham ischemic group.
at the light microscope level in the glomeruli from the However, tubular and interstitial cell proliferation was
various groups. increased following treatment with the ETA/ETB recep-
Interstitial area. Interstitial area was increased in the tor antagonist as compared with both the sham ischemic
saline ischemic group as compared with the sham ische- group (P , 0.05; Fig. 4) and the saline ischemic group
mic group (P , 0.05; Table 2). There was a significant (P , 0.05). Decreases in PCNA staining for both cell
decrease in interstitial area in the ETR antagonist-treated types were observed in the ETA group as compared with
ischemic groups as compared with the saline ischemic the saline ischemic group (P , 0.05).
group (P , 0.05). TUNEL and apoptosis. TUNEL-positive cells were
Monocyte and macrophage infiltration. ED-1 staining demonstrated in all groups. The numbers were less than
was increased in the saline ischemic group as compared 0.2% in any group. There was a decrease observed in
with the sham ischemic control group (P , 0.05; Table apoptosis of tubular cells in the ETA group as compared
2). Groups treated with ETR antagonists showed a reduc- with both the saline ischemic and the sham ischemic
tion in Mo and M f as compared with the saline ischemic groups (P , 0.05; Fig. 5). The number of TUNEL-posi-
group, although the ETA/ETB group remained higher tive interstitial cells was decreased in both of the ischemic
than the ETA group (P , 0.05). groups treated with ET receptor antagonists and the
Myofibroblast accumulation. Staining for a-smooth sham ischemic group as compared with the saline ische-
muscle actin was increased in the saline ischemic and in mic group (P , 0.05).
the ETA/ETB group as compared with sham ischemic
group (P , 0.05; Fig. 3A). Animals in the ETA group
DISCUSSIONhad decreased staining for a-SMA as compared with the
This study identified long-term consequences of renalsaline ischemic group (P , 0.05).
ischemia and a beneficial treatment using the ETA recep-Tubulointerstitial collagen III. There was a significant
increase in collagen III observed in the saline ischemic tor antagonist SB 234551. Saline-infused ischemic groups
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Fig. 2. Silver masson trichrome staining of tissue sections. (a) ETA antagonist (SB 234551) group 3100. (b) ETA antagonist 3400. (c) ETA/ETB
antagonist (SB 209670) group 3100. (d) ETA/ETB 3400. (e) Saline ischemic group 100. (f) Saline ischemic group 3400. (g) Sham ischemic group
3100. (h) Sham ischemic group 3400.
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Table 2. Pathological data for all groups at six months
Saline SB 234551 SB 209670 Sham
ischemic ETA ETA/ETB ischemic
Parameter N 5 8 N 5 8 N 5 7 N 5 8
Interstitial area % FA 16.6160.70 10.9660.18a 10.8960.26a 11.2660.26a
Monocytes and macrophages N/0.91 mm2 4.3360.47 1.2960.26a 2.5760.54a 1.6160.28a
Collagen IV % FA 5.5860.59 5.3960.73 6.0460.89 5.2360.94
Abbreviations are: ET, endothelin; FA, fractional area.
Fig. 4. Morphometric quantitation of proliferating (PCNA-positive)
cells. *P , 0.05 as compared with sham ischemic group; #P , 0.05 as
compared with saline ischemic group (N 5 8 for each group). Symbols
are: (j) PCNA total; ( ) tubular; ( ) interstitial; (h) other (refers
to vascular and glomerular cells).
Fig. 3. Morphometric quantitation of (A) myofibroblasts (a-SMA) and
(B) interstitial collagen III. #P , 0.05 as compared with saline ischemic
group; *P , 0.05 as compared with sham ischemic group. Standard
errors of the mean are shown by the error bars on all graphs (N 5 8
for each group).
showed increases in systolic blood pressure, interstitial Fig. 5. Morphometric quantitation of TUNEL-positive cells. Symbols
area, Mo and M f , myofibroblasts, collagen III, and pro- are: (j) TUNEL total; ( ) tubular; ( ) interstial. *P , 0.05 as com-
pared with sham ischemic group; #P , 0.05 as compared with salineliferating cells as compared with sham ischemic animals.
ischemic group (N 5 8 for each group).These changes were ameliorated by ETA receptor antag-
onism. Conversely, the ETA/ETB receptor antagonist SB
209670 had detrimental effects on kidney function and
pathology for all parameters studied apart from collagen level. There was also an increase in interstitial area,
which was accompanied by increases in the number ofIV, systolic blood pressure, and interstitial area.
Our previous work has suggested the presence of long- Mo, M f , and myofibroblasts. In the present study, treat-
ment with the ETA receptor antagonist ameliorated theseterm consequences of renal ischemia [3]. At 64-days post-
ischemia, there was an accumulation of collagen III at changes at six-months postischemia.
Decreases in renal function, as measured by GFR andthe corticomedullary junction in ischemic groups. At six
months, this increase appeared to remain at a similar creatinine clearance, were not evident at six months fol-
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lowing renal ischemia in the saline ischemic group. Se- The beneficial effects of ETA receptor antagonism are
rum creatinines, urinary protein, and albumin were in- obvious from the data mentioned previously in this arti-
creased, however, as compared with the sham ischemic cle, and therefore it may be suggested that the detrimen-
group. These changes are consistent with those of Azuma tal effects of SB 209670 may be due solely to the blockade
et al, who demonstrated no increase in proteinuria in of the ETB receptor. There are many reasons why this
animals with only one kidney until 24-weeks postische- may be the case. The ETB receptor is involved in the
mia, with a second increase at 52 weeks [1]. synthesis of the vasodilator nitric oxide (NO) by endo-
Systolic blood pressure in the saline ischemic group thelial cells, through activation by either ET-1 [25] or
was increased as compared with ischemic groups treated ET-3 [26]. It could be then surmised that blockade of
with ET receptor antagonists and the sham ischemic the ETB receptor may increase renal vascular resistance,
group. This was expected, as ET is well cited in the contributing to reperfusion injury. Inhibition of NO has
literature as increasing systolic blood pressure [22]. Mor- also been associated with an increase in leukocyte adhe-
tensen et al have shown that infusion of ET-1 into rats sion to mesenteric venules [27], suggesting that the in-
for seven days causes chronic hypertension [23]. This creases in Mo/M f infiltration are attributable to deficits
indicates that the effects of ET at early time points may in NO production, which are not overcome by the bene-
be significant later on. It is plausible to suggest that ET ficial effect of blockade of the ETA receptor. Schaffer et al
receptor blockade would reduce blood pressure at six suggested that NO is an autocrine regulator of fibroblast
months, and this was found to be the case, although this synthesis of collagen [28]. This is consistent with data
may be an indirect effect. for the ETA/ETB group showing increases in collagen IIIPathological changes following ischemia were consis- and accumulation of myofibroblasts not evident in the
tent with those found previously by our group with in-
ETA group. Another possible explanation for the detri-creases maximal at 8 days postischemia then returning
mental effect of ETA/ETB blockade is the involvement ofto basal levels by 32 days, with further numerical in-
the ETB receptor in the clearance of ET. If ETB receptorcreases at 6 months postischemia [3]. Increases in Mo
blockade occurred, then theoretically, the removal of ETand Mf , MF, collagen III, and interstitial area were iden-
would be reduced.tified in the saline ischemic group at six-months postis-
A third explanation for the apparent difference be-chemia. These are all markers of ongoing renal disease,
tween ETA and ETB receptor blockade is a difference inperhaps indicating that there is disease progression fol-
the affinity of the ETA component of SB 234551 and SBlowing renal ischemia in the long term [24]. Cellular
209670. The receptor affinity of SB 234551 (0.1 mmol/L)proliferation was also increased in tubule cells of the
is double that of SB 209670 (0.2 nmol/L), and therefore,saline ischemic group. The reasons for this reactivation
the differences noted may be due to the ETA/ETB recep-of pathology are unclear. The pathological changes iden-
tor antagonist not providing a substantial blockade oftified in the saline ischemic group at six months are
the ETA receptor. While this may be the most likelyameliorated with ETA receptor antagonism with SB
explanation, further studies need to be performed to234551, which is consistent with previous studies showing
ascertain it.early improvements in renal pathology following treat-
In summary, our study confirms that there are long-ment with ET receptor antagonists postischemia [9–12].
Although the incidence of apoptotic cells was small, term pathological consequences of renal ischemia.
there was a significant difference observed between sa- Blockade of ETA receptors by SB 234551 is beneficial in
line and sham ischemic groups. IARF at six-months postischemia; however, blockade of
In contrast to ETA receptor antagonist SB 234551, ETA and ETB with SB 209670 may be detrimental to
blockade of both ETA and ETB receptors by SB 209670 long-term kidney function.
produced detrimental effects on the kidney at six months
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